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Background: Non-small cell lung cancer, breast cancer, and colorectal cancer are commonly diagnosed cancers in
Canada. Patients diagnosed with early-stage non-small cell lung, breast, or colorectal cancer represent potentially
curable populations. For these patients, surgery is the primary mode of treatment, with (neo)adjuvant therapies
(e.g., chemotherapy, radiotherapy) recommended according to disease stage. Data from our research in Nova
Scotia, as well as others’, demonstrate that a substantial proportion of non-small cell lung cancer and colorectal
cancer patients, for whom practice guidelines recommend (neo)adjuvant therapy, are not referred for an oncologist
consultation. Conversely, surveillance data and clinical experience suggest that breast cancer patients have much
higher referral rates. Since surgery is the primary treatment, the surgeon plays a major role in referring patients to
oncologists. Thus, an improved understanding of how surgeons make decisions related to oncology services is
important to developing strategies to optimize referral rates. Few studies have examined decision making for (neo)
adjuvant therapy from the perspective of the cancer surgeon. This study will use qualitative methods to examine
decision-making processes related to referral to oncology services for individuals diagnosed with potentially curable
non-small cell lung, breast, or colorectal cancer.
Methods: A qualitative study will be conducted, guided by the principles of grounded theory. The study design is
informed by our ongoing research, as well as a model of access to health services. The method of data collection
will be in-depth, semi structured interviews. We will attempt to recruit all lung, breast, and/or colorectal cancer
surgeons in Nova Scotia (n ≈ 42), with the aim of interviewing a minimum of 34 surgeons. Interviews will be
audiotaped and transcribed verbatim. Data will be collected and analyzed concurrently, with two investigators
independently coding and analyzing the data. Analysis will involve an inductive, grounded approach using constant
comparative analysis.
Discussion: The primary outcomes will be (1) identification of the patient, surgeon, institutional, and health-system
factors that influence surgeons’ decisions to refer non-small cell lung, breast, and colorectal cancer patients to
oncology services when consideration for (neo)adjuvant therapy is recommended and (2) identification of potential
strategies that could optimize referral to oncology for appropriate individuals.
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Lung cancer, breast cancer (BC), and colorectal cancer
(CRC) are extremely common in Canada. In 2011, it was
estimated these three cancers accounted for 40% of all
new cancer diagnoses nationally [1]. These three cancers
also represent the leading cancer causes of death in
Canada, accounting for 46% of all cancer deaths in
2011 [1]. In Nova Scotia (NS), the incidence rate of BC
in females is similar to the national incidence rate, while
the incidence rates for lung cancer and CRC are higher
in NS for both males and females than national rates [1].
Cancer is a complex disease, often involving multiple
healthcare providers from different clinical specialties.
For patients with potentially curable disease, compre-
hensive care involves a sequence of events along a care
trajectory that starts at a positive screen or first presen-
tation of signs/symptoms to completion of all adjuvant
therapies and ongoing surveillance. In regards to treat-
ment, several distinct modalities may be used singly or
in combination in an effort to achieve optimal patient
outcomes (e.g., long-term survival). Patients diagnosed
with early-stage non-small cell lung cancer (NSCLC), BC,
or CRC represent potentially curable populations. For
these individuals, surgical resection is the primary mode
of potentially curative treatment, with (neo)adjuvant
therapies provided according to clinical and/or patho-
logical stage of disease.
Following surgical resection of the cancer, adjuvant
therapies (e.g., chemotherapy, radiotherapy, hormonal
therapy) may be recommended, depending on stage and
evidence of benefit, to eradicate loco-regional or systemic
microscopic residual disease. Without such therapy, the
risk of recurrence with surgical resection alone may be
high [2-4]. For some cancers, therapies may be recom-
mended before the surgery in an effort to decrease tumor
size (“downstage”) and thus facilitate surgical resection,
treat micrometastatic disease, and, in some situations,
improve important patient-centered outcomes (e.g.,
morbidity). In such instances, the therapy is termed
neoadjuvant, indicating it occurs prior to surgery, to
distinguish it from adjuvant therapies in the postopera-
tive period.
Unlike many malignancies (e.g., prostate cancer [5]),
treatments for NSCLC, BC, and CRC are relatively stan-
dardized for the majority of patients receiving potentially
curative resection. Indeed, large, randomized clinical trials
have demonstrated that receipt of adjuvant chemother-
apy improves overall survival in NSCLC, BC, and CRC
patients with high-risk disease [6-13]. Consequently,
clinical practice guidelines (CPGs), which provide syn-
theses of the best available evidence, recommend spe-
cific (neo)adjuvant therapies for patients with stage II/
IIIA NSCLC, stage I–III BC, stage II/III rectal cancer,
and stage IIB/III colon cancer [14-19].Variations in treatment practices for potentially curable
patients
Despite clinical trials demonstrating clear efficacy, the
impact of beneficial (neo)adjuvant therapies in patients
diagnosed with cancer will ultimately depend on their
uptake in patient populations outside of those trials [20].
Health-services research has consistently identified a
gap between what is identified as “best practice” (as
determined by scientific evidence, largely acquired via
randomized clinical trials) and what actually happens in
clinical care [21-27]. Many factors have been shown to
influence awareness of, agreement with, adoption of, and
adherence to best practices (i.e., CPGs). These include
the needs and expectations of patients, characteristics
of patients and providers, nature of the evidence and
its mode of delivery, setting or context of care, and
organizational and system constraints or enablers [28-
34]. Studies in Canada have revealed variations in
(neo)adjuvant therapy rates for appropriate patients, with
patient (e.g., age [20,22,27,35-39], comorbidities [36],
place of residence [35,37,40]) and health-system (e.g.,
prevailing wait times [40,41], centralized cancer services
[42]) factors associated with these variations. The large
variations by age, with older-aged individuals less likely to
receive recommended care, demonstrate an age-specific
bias toward no treatment, which is not necessarily sup-
ported by scientific evidence; in CRC, for example,
advanced age has not been associated with lack of a sur-
vival benefit nor with increases in chemotherapy-induced
toxicities [10,43,44].
While CPGs are meant to guide decision making related
to treatment options, and non-receipt of (neo)adjuvant
therapy may be entirely appropriate given the circum-
stances of individual patients, one could argue that hav-
ing a discussion (or “consultation”) regarding the role of
(neo)adjuvant therapy with a physician who specializes in
(neo)adjuvant therapies represents the ideal management
scenario for patients with potentially curable disease and
in whom (neo)adjuvant therapy has been shown to be
beneficial. Though there is no defined “ideal” benchmark
for referral or consultation rates, both referral to and
consultation with an oncologist have been identified as
measures of quality care for patients with resected
(or resectable) disease [45-47]. Canadian studies examin-
ing surgeon referral patterns at single tertiary care insti-
tutions report relatively low referral rates to oncology for
resected NSCLC patients [48,49] and large variations in
referral patterns by patient characteristics for resected
CRC patients [36].
Despite the existence of CPGs, clinicians from mul-
tiple specialties may have varying perspectives on the
benefits/risks of cancer treatment, as well as different
interpretations of an increasingly complex evidence base.
Researchers have found that surgeons and oncologists
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adjuvant therapies for BC [50] and CRC [51] patients,
while preferred approaches for the management of
NSCLC patients vary widely across and within medical
and surgical specialties [52]. Thus, the extent to which
various specialists become involved in patient care may
affect patient decisions related to (neo)adjuvant therapies
and the quality of care ultimately received. Referral to an
oncologist has been identified as one of the key factors
associated with receipt of chemotherapy [53-55].
An assessment of referral and consultation rates in Nova
Scotia
In NS, we have comprehensively examined health-service
utilization related to (neo)adjuvant therapy, including
referral to an oncologist, oncologist consultation, and
receipt of (neo)adjuvant therapy, for all patients diag-
nosed with CRC over a five-year time period [56]. Our
findings revealed that a substantial proportion of patients
for whom guidelines recommend consideration for (neo)
adjuvant therapy, were not referred to the cancer center
for a medical or radiation oncologist consultation. Specif-
ically, we found that approximately one-third of resected
stage II/III rectal cancer patients were not referred for a
radiation oncology consultation (either in the neoadju-
vant or adjuvant settings), and more than 20% of resected
stage IIB/III colon cancer patients were not referred for a
medical oncology consultation (unpublished data). Once
referred, however, the vast majority of patients (>97%)
received the consultation. Furthermore, our population-
based research demonstrated that the most common rea-
son for not receiving adjuvant chemotherapy in CRC
patients for whom chemotherapy is recommended was
not having a medical oncology consultation (representing
53% of patients who did not receive chemotherapy) [39].
While these findings may suggest an early selection of
patients who were deemed not candidates for (neo)adju-
vant therapy, they also point toward the need to better
understand the patient, surgeon, institutional, and
health-system factors that influence referral to oncology
services in NS [39].
For NSCLC, Younis and colleagues [20] found that
73% of resected, stage II–III NSCLC patients in NS in
2005 received a referral to medical oncology for discus-
sion of adjuvant chemotherapy. Crude data estimates
from the Nova Scotia Cancer Registry suggest that refer-
ral rates for BC are higher than those for NSCLC and
CRC, with referral rates in six of nine health districts
approaching or reaching 100% (unpublished data). These
data corroborate clinical experience, which suggests that
surgeons in NS are more likely to refer BC patients to an
oncologist for a discussion on the role of adjuvant ther-
apy than NSCLC or CRC patients, despite the fact that
many NS surgeons perform both BC and CRC surgeryand thus appear to be acting differently for BC versus
CRC patients. Taken together, these research and clinical
observations reinforce the need to better understand the
multiple factors that influence surgical decision making
related to (neo)adjuvant therapies.
Surgeon decision making with respect to cancer
treatment(s)
Since surgical resection represents the primary treatment
for patients with potentially curative NSCLC, BC, and
CRC, the surgeon is chiefly responsible for referring
patients to medical and/or radiation oncologists for dis-
cussions about (neo)adjuvant therapy. The surgeon also
plays a role in the decision to offer (neo)adjuvant
therapies (along with the oncologist) and to receive
(neo)adjuvant therapies (along with the oncologist and
patient). The decision to refer or to recommend therapy
is not unlike other patient management decisions, which
are invariably made in the midst of uncertainty as the
surgeon considers factors such as the patient’s risk of dis-
ease recurrence, life expectancy, comorbid conditions,
and preferences, as well as information about the treat-
ment and its potential benefits/costs. As such, surgeons
may find themselves weighing the probability of clinical
benefit versus potential or probable “costs” such as treat-
ment toxicities, patient (non)compliance, patient difficulty
accessing cancer treatment facilities, patient lodging and
transportation expenditures associated with receiving
care (which can represent significant out-of-pocket costs
in Canada[57,58]), or even the human or financial
resources expended (and possibly denied other patients).
For example, population-based studies in the United
States [59,60] have demonstrated that a BC patient’s dis-
tance to a radiotherapy facility is strongly associated with
the type of surgery she receives (e.g., breast conservation
versus mastectomy; radiotherapy is recommended fol-
lowing breast conservation surgery to reduce recurrence
rates [61,62]), suggesting that the structure/centralization
of cancer services does influence surgeons’ decisions
related to cancer treatment(s). Moreover, health-system
factors shown to affect patient utilization of cancer ser-
vices in Canada, such as prevailing wait times [40,41,63],
may also influence surgeons’ decisions to refer patients
for a medical or radiation oncology consultation [64].
While population-based studies have demonstrated that
variations in referral, consultation, and (neo)adjuvant ther-
apy rates are associated with patient, provider, and health-
system factors, the multiple factors that influence the
process of decision making among cancer surgeons are
not well understood. In Canada, research has been con-
ducted into surgeon adoption of sentinel lymph node
biopsy for BC and the factors influencing adoption. An
initial survey of surgeons who treat BC across Canada
found that, for the 39% of surgeon respondents who
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most commonly cited reasons were inadequate resources
(53%), lack of evidence to support the procedure (24%),
and lack of comfort with the technique (22%) [65], sug-
gesting that factors at multiple levels of the system (e.g.,
the evidence itself, the provider, and the institution)
influence the decision to adopt this evidence-based
practice. In a follow-up to this research, Wright and
colleagues [66] conducted a qualitative study to gain a
more in-depth understanding of the multiple factors that
influence sentinel lymph node biopsy adoption. They
found that the presence of a high-volume local surgical
champion, interprofessional collaboration, institutional
support, and the existence of internal hospital protocols
and provincial-level CPGs all influenced surgeons’ deci-
sions to adopt this surgical procedure. In regards to
decision making about (neo)adjuvant therapies, numerous
researchers across Canada, all of whom have reported var-
iations in referral rates and receipt of oncology services,
have called for more in-depth study of referral and treat-
ment patterns to improve our ability to develop more
effective ways of optimizing care for patients with po-
tentially curable disease [27,36,39,67].Rationale for proposed study
Worldwide, it has been estimated that one-third of
cancer cases could be prevented and another one-third
cured if practices consistently complied with CPGs [68].
In Canada, the Canadian Strategy for Cancer Control
estimated that cancer outcomes could be improved by
30% with the appropriate application of existing evidence
[69]. Receipt of (neo)adjuvant therapies for resected
patients at high risk of recurrence is an essential compo-
nent of this evidence. While a proportion of patients
not referred to oncology services may be appropriately
deemed poor candidates for (neo)adjuvant therapy, there
may be other factors that influence the decision not to
refer and thus prevent patients from receiving a medical
or radiation oncologist consultation. Since surgeons act
as the main “gatekeeper” to the organized cancer system,
understanding how they make decisions related to oncol-
ogy services is important to developing appropriate strat-
egies and interventions to optimize referral rates and
utilization of oncology services.
This study will use qualitative methods to examine
decision-making processes related to referral to oncology
services for individuals diagnosed with potentially curable
NSCLC, BC, and CRC. These cancer sites were chosen
for the following reasons:
1. High incidence [1]
2. Existence of clear, relatively standardized treatment
practices for these diseases in the (neo)adjuvantsetting, with evidence that adherence to best
practices improves patient outcomes
3. For NSCLC and CRC, it has been demonstrated that
a substantial minority of potentially curable patients
in NS are not being referred for an oncology
consultation [20,39,56]
4. Based on surveillance data and clinical experience,
nearly all potentially curable stage I–III BC patients
are referred for an oncology consultation in NS, even
though most of the same surgeons are performing
CRC surgeries, making BC a valuable and
informative disease site to compare and contrast
surgeon referral practices
Together, these reasons underscore the need for fur-
ther study of referral decisions/behaviors in NS. Most
researchers who study the adoption and implementation
of best practices in healthcare emphasize the necessity
of developing a good understanding of the influences on
current practice in order to design more effective inter-
ventions [30,31,70].
Research objectives
Through qualitative inquiry, surgeons will be asked to
reflect on their decision-making processes related to
referral to oncology services for potentially curable
NSCLC, BC, and CRC patients, and on the specific
factors that influence their decision to refer (or not).
The primary objectives are to
1. Identify surgeons’ perspectives on the patient,
surgeon, institutional, and health-system factors that
influence their decision to refer patients to oncology
services;i. Explore whether surgeons use a mental “threshold
of benefit” schema for oncology services and, if so,
how they weigh the benefits and costs of an
oncology consultation/(neo)adjuvant therapy;
2. Identify the perceived barriers and enablers to
referral to oncology services;
3. Explore whether the factors that influence decision
making differ by disease site, specifically between
patients diagnosed with BC versus patients diagnosed
with NSCLC or CRC;
4. Identify potential strategies to promote referral to
oncology services for patients for whom (neo)
adjuvant therapy is recommended.
Related to objective 1, we will attempt to identify
whether and how patient (e.g., age, health status/comor-
bid conditions, preferences for care), surgeon (attitudes/
beliefs related to patients, awareness of evidence/CPGs
Table 1 Six dimensions related to access to health
services
Dimension Examples
Availability Resources (personnel, equipment, technology),
prevailing wait times
Accessibility Centralized services, “close to home,” transportation
difficulty
Accommodation Coordination and integration of services, “satellite’
cancer clinics,” telemedicine
Affordability Funding of cancer services, insurance/drug coverage,
indirect patient costs (lodging, transportation)
Acceptability Patient and provider attitudes toward one another,
patient characteristics (e.g., age, sex, comorbid
conditions, life expectancy), patient preferences,
provider characteristics (e.g., sex, years of practice,
level of specialization, surgery volume)
Awareness Patient and provider awareness of evidence for
therapy, clinical practice guidelines, structures
that support multidisciplinary dialogue/consultation
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surgery volume), institutional (e.g., academic versus com-
munity hospital, structures to facilitate collaborative
decision making [e.g., access to multidisciplinary tumor
boards], internal/hospital protocols), and health-system
(e.g., availability of cancer system resources, accessibility
of oncologists/cancer centers, availability/dissemination
of provincial-level CPGs) factors influence surgeons’
decision to refer patients to oncology services. Through
qualitative inquiry, this study will seek to explore how
surgeons evaluate the relative importance of these fac-
tors, or weigh the perceived benefits and costs, to come
to a decision to refer (or not refer) their NSCLC, BC, or
CRC patients for a medical or radiation oncology
consultation.
Conceptual framework
This study is informed by our ongoing research in health
services and implementation science [39,71-82], as well
as an established model of access to health services [64].
Like all care providers, surgeons operate within a com-
plex healthcare delivery system that is situated in a his-
torical, social, economic, and political context. As a
result, decisions related to (neo)adjuvant treatment are
likely related to patient factors (e.g., functional status/
comorbidities, life expectancy, and risk of disease recur-
rence), surgeon factors (e.g., level of training/specialization,
personal beliefs [52,83]), considerations of treatment
benefits and risks, and the broader health system in
which they operate. The Penchansky and Thomas [64]
model of access to health services provides an approach
to understanding access to healthcare that focuses on
understanding the “fit” between a patient’s needs and the
system’s ability to meet those needs. The model posits
that “fit” can be measured through five dimensions,
which relate to patient, provider, and health-system
factors: availability (volume of physician and other
healthcare resources), accessibility (geographic relation-
ship between the users and providers of healthcare),
accommodation (organization of care), affordability (costs
of providing/receiving care), and acceptability (attitudes
and characteristics of patients and providers). More re-
cently, MacKillop [84] presented another important di-
mension of access: awareness of services and indications
for their use. For example, a referring physician must be
aware of indications for potentially beneficial services
and that those services are available to the patient. Table 1
provides further detail on these six dimensions.
Design and methods
A qualitative research design using semi structured
interviews will be used in this study. Qualitative data
“document the world from the point of view of the
people studied” (p. 165) [85], thereby providing insightinto how people make sense of their experiences. Such
insight cannot be easily provided by other methods [86].
Qualitative research is often used when there is little
existing knowledge (or data) regarding the research topic
and to help explain and/or interpret the results of quan-
titative research [87,88].
Methodology
This qualitative study will be guided by the principles
of grounded theory [89], which attempts to move
beyond description and generate a general explanation
(a “theory”) of a process or action that is shaped by the
views of participants who have experienced the process
or action. Grounded theory is “grounded” in the sense
that findings tend to be inductively derived from the
data and the participants themselves.
According to the methods of grounded theory, con-
cepts and categories are identified and developed as the
research is being conducted [89]. While the emphasis of
this methodology is on the inductive nature of theory
building, Strauss and Corbin [89] do not object to the
use of pre-existing theory per se, but rather in the way
it might be used to influence the research process (e.g.,
by leading the researcher down a path of anticipated
findings or assumptions). As Gerson [90] has demon-
strated, a sophisticated grounded theory approach rejects
the simplistic notion that theory building is entirely in-
ductive (or deductive); instead, theory building occurs
in an ongoing dialogue between pre-existing theory
and new observations/insights generated from empirical
research.
Semi structured interviews
In-depth, semi structured interviews will be conducted
with NS thoracic, breast, and colorectal surgeons to gain
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sions to refer patients to oncology services. The value of
interviewing is that we can discover understanding about
people and their actions that cannot be observed: “[w]e
cannot observe how people have organized the world
and the meanings they attach to what goes on in the
world. We have to ask people questions about those
things” (p. 341) [87]. The semi structured interviews will
be face-to-face or telephone interviews depending upon
practical considerations, such as travel distance to inter-
view a limited number of participants.
Open-ended questions and related probes will be
drafted based on the research objectives, team members’
clinical experiences, and the Penchanksy and Thomas
model [64], with the latter providing further insight into
the patient, surgeon, institutional, and health-system
factors influencing utilization of health services. Since
decisions around not to refer/treat are made in the con-
text of individual patients, the script will also include
scenario-like questions to explore, in a more in-depth
manner, how surgeons consider (or weigh) various fac-
tors (e.g., relative survival benefit, comorbidities). Inter-
view questions will be adapted for thoracic, breast,
and colorectal surgeons since NSCLC, BC, and CRC
are different diseases that require different treatment
approaches, each with varying degrees of relative benefit.
Collectively, the questions will seek to understand how
surgeons experience the process of deciding to refer
patients for oncology consultation and to identify the
factors that influence this process. Two pilot interviews
will be conducted with surgeons not part of the research
team. These will be audiotaped, transcribed verbatim,
and discussed amongst the entire research team to en-
sure that all topics of interest are explored. The inter-
view script will be refined through these pilot interviews.
Consistent with grounded theory principles, the inter-
view guide will be employed in a formative manner and
adapted during data collection on the basis of previous
interview findings to further explore important concepts
and emerging categories [87,91].
One investigator [RU], who is experienced in qualita-
tive methods, will carry out all interviews.
At the beginning of each interview, descriptive infor-
mation related to the surgeon (e.g., years of practice,
level of specialization, cancer surgery volume) and insti-
tution (e.g., presence of internal/ hospital protocols,
access to multidisciplinary tumor boards) will be collected
using a standardized data collection form. Regardless of
interviewing mode (face-to-face or telephone), the
interviews will be open and characterized by a personal
approach, meaning that the interviewer will have a prior
understanding of the background and work of the parti-
cipants, ensure that the participants clearly understand
the study objectives and interview procedure, andencourage the participants to express their opinions by
explaining that all answers are valid/valuable and will be
included in the analysis. Our experience is that such an
approach results in encounters that are more like conver-
sations than structured interviews with a series of fixed
questions [88]. All interviews will be audiotaped to
ensure the data are captured and retrievable in true form
and transcribed verbatim by a research coordinator with
experience in transcription. The audiotapes and tran-
scripts will be supplemented with field notes (or memos),
allowing the interviewer to highlight particularly insightful
data and to capture personal reflections during data col-
lection. Transcripts will be verified by listening to the
audiotapes. Following each interview, the questions and
responses will be reviewed to determine whether or not
the issues were answered in sufficient depth and, if not,
to revise the questions before the next interview [91].Study participants
In grounded theory, the point is to gather enough data to
fully develop (or saturate) the explanation [89]. Since
there are only a limited number of surgeons in NS who
perform NSCLC, BC, and/or CRC surgery (n ≈ 42), we
will attempt to recruit all of these surgeons for this study.
We will include the data from the pilot interviews with
all interview data, with pilot participants’ permission.
Recruiting all surgeons will provide a sample with differ-
ences in career stage (junior, senior), level of training
(general surgeon, surgical oncologist), and practice
location (community hospital, academic/tertiary care
center). Recognizing that not all surgeons may agree to
participate, we aim to interview a minimum of 34 sur-
geons (80% of relevant surgeons). Our prior experiences
surveying rectal cancer surgeons [92] and interviewing
breast and colorectal surgeons [unpublished data] in NS
suggest this participation rate is achievable.
While recruitment in grounded theory is based on
theoretical sampling and saturation, we will attempt to
recruit all surgeons due to the relatively small number
of surgeons in NS who perform these surgeries. None-
theless, we will discontinue data collection if we reach
saturation before all surgeons are asked to participate.
When/if we determine we are nearing theoretical satur-
ation, but some categories (or properties of categories)
require further examination, we will make strategic
decisions about who will provide the most information-
rich source of data to meet our analytic needs (i.e.,
theoretical sampling).Recruitment methods
Two investigators [RU, GAP] will identify all potential
participants and initially approach each potential partici-
pant in person or via email or telephone to briefly
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participate. If the participant responds in the affirmative,
a research coordinator will follow up with the partici-
pant to discuss in detail the nature and purpose of the
study and to arrange for a time to conduct the informed
consent discussion and interview. If a potential partici-
pant fails to respond to the initial contact within one
week, an investigator [GAP or RU] will follow up with
him/her via telephone.Anticipated ethical issues
The study poses no serious ethical problems. Ethical
approval to conduct this study has been obtained from
Capital District Health Authority. Written informed
consent will be obtained from each participant. This will
include permission to audiotape the sessions and to use
anonymized quotes. Any publication will not attribute
specific comments to identifiable participants. Partici-
pants’ geographic locations (e.g., health region) will not
be identified; rather, participants will be described as
practicing in community or academic settings.Analysis
Data will be collected and analyzed concurrently,
allowing emergent concepts and categories to be incor-
porated and explored in subsequent interviews. An
inductive, grounded approach, using constant compara-
tive analysis, will be used for qualitative analysis of inter-
view transcripts and field notes [89]. Grounded theory
analysis involves coding; constant comparison; and
identification, organization, and refinement of categories.
Specifically, the analytic process will entail reading and
rereading of transcripts, development of a coding scheme
reflecting unique ideas and concepts, application of the
coding scheme to the interview text, and grouping of
coded text into categories relevant to the study objectives.
Identifying codes is a critical component of the data
analysis stage. Coding is defined as the process of group-
ing participants’ responses into categories that bring to-
gether similar ideas, concepts, or themes that the
researcher has discovered through familiarity with the
interviews and text [91]. Code words reflect the essence
of the data and lead to ease of recognition as the number
of coded words increase. Consistent with constant com-
parative analysis, open and axial coding of interview
transcripts will occur simultaneously. Open coding entails
reading the transcribed interviews line by line in their
entirety to identify ideas and concepts and then group-
ing concepts to form categories and subcategories. This
process also involves routinely revisiting previous codes
for refining purposes.
Axial coding is used to make connections between the
categories and subcategories of codes. Repeating ideasare brought together, leading to the reduction and clus-
tering of categories based on content similarity. These
categories will be reviewed and refined based on their
relationship to one another and their ability to explain
the factors that influence decision-making processes
related to referral to oncology services for NSCLC, BC,
and CRC. This process will involve ongoing review of
the emerging analysis to determine whether and how to
expand or merge categories, which will help to ensure
that they are reflective of the interview data.
The final stage of analysis will be selective coding, or
the detailed development of categories, selection of a
core theoretical category, and integration of categories.
Specifically, Strauss and Corbin [89] describe selective
coding as “the process of selecting the central or core
category, systematically relating it to other categories,
validating those relationships, and filling in categories
that need further refinement and development” (p. 116).
The core category should have the analytic strength to
“pull the other categories together to form an explana-
tory whole” (p. 146). However, it must be noted that,
for selective coding, theoretical saturation should be
reached. Therefore, the analytic process may be limited if
we have interviewed all relevant, participating surgeons
but have not reached saturation. Nonetheless, identifica-
tion of categories, linking of categories and subcategories,
and clustering around a core or central concept will help
us develop a theory (or the building blocks of a theory)
that deepens understanding and facilitates action in this
important clinical area.
Data will be coded and analyzed independently by two
investigators [RU, CK]. These investigators will develop
an electronic codebook to guide the coding scheme and
subsequent categorization of data; this will be achieved
through iterative discussion throughout the data analysis
process. The codebook will contain code definitions,
sample data illustrating application of the code, and
decision rules related to each code. Qualitative analysis
will be performed manually, with the assistance of quali-
tative software (NVivo; QSR International, Cambridge,
MA, USA) for data management and to enable com-
parison and synthesis of codes. To improve the reliability
of findings, a third investigator [JS] will review the
codebook, all analytic decisions, and sample transcripts
or sections of transcripts. We will resolve disagreement
among investigators through discussion and, when
needed, reexamining transcripts and coded data. To
ensure consistency and authenticity of the entire qualita-
tive process, preliminary findings will also be discussed
with the three members of the research team who are
practicing cancer surgeons in NSCLC, BC, and CRC
[GAP, PJ, GB]. The final categories will be presented in
diagrams to visually represent the conceptual relation-
ship among categories, tabular form to address each
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as well as the broader scientific literature.
Strategies for increasing rigor
Numerous steps consistent with qualitative research will
be taken to ensure the overall rigor of the proposed
study. These include field journal/note-taking during
interviews; detailed documentation of methodological
and analytic decisions (i.e., an audit trail) to clearly illus-
trate the means of arriving at the codes and findings and
to avoid overgeneralization and unsubstantiated conclu-
sions; systematic data coding and analysis; use of direct
quotations to ensure the perspectives of the participants
are represented as clearly as possible and to provide the
reader with a clearer sense of the evidence on which the
findings and interpretations are based; member checking
by sending interview participants a summary of the main
findings extracted from their interview; review of the
data coding process, analytic decisions, and resultant
themes by three investigators [RU, CK, JS]; and review
and in-person discussion of preliminary findings by three
investigators who are practicing cancer surgeons [GAP,
PJ, GB]. Importantly, triangulation of findings by the
research team and high levels of team involvement
throughout data analysis and interpretation enhance
rigor by minimizing the chance that important thematic
ideas go unnoticed and helping to ensure that the
organization of data and the resulting conclusions are
transparent.
Discussion
The primary outcomes of this study will be (1) identifi-
cation of the patient, surgeon, institutional, and health-
system factors that influence surgeons’ decisions to refer
NSCLC, BC, and CRC patients to oncology services when
consideration for (neo)adjuvant therapy is recommended
and (2) identification of potential strategies (interventions)
that could increase referral to oncology for appropriate
individuals. The findings from this study will help fill an
important gap in our understanding of how surgeons
make decisions in regards to their patients and how (and
the extent to which) organizational and health-system
factors can influence decision making during the clinical
encounter. As such, the knowledge gained will support
the development and implementation of appropriate
strategies to optimize referral rates and access to oncology
services. Depending on the surgeon-identified influential
factors, strategies could target the patient level (e.g.,
patient decision aids, shared decision-making models),
surgeon level (e.g., focused educational activities, audit
and feedback), and/or organizational/policy level (e.g.,
performance monitoring systems, expansion of multi-
disciplinary tumor boards, use of telemedicine) of the
health system. For example, expansion of multidisciplinarytumor boards across the province, or introduction of
telemedicine services to permit “just-in-time” surgeon
and/or patient consultation with an oncologist at a cancer
center, may increase collaborative decision making and
optimize referrals to oncology services [39], and support
co-management options for community-based surgeons
who do not have regular opportunities to interact with
other cancer specialists [93].
In summary, receipt of (neo)adjuvant therapies for
appropriate patients is an essential component of
evidence-based practice for NSCLC, BC, and CRC
patients. In NS, prior research indicates that a substantial
proportion of NSCLC and CRC patients for whom CPGs
recommend consideration for (neo)adjuvant therapy are
not referred for a medical or radiation oncologist con-
sultation. Since surgeons act as a “gatekeeper” to the
organized cancer system, understanding how they make
decisions related to oncology services is important to
developing appropriate strategies and interventions to
optimize referral rates and improve access to these
services.
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